Vera Belaoussoff
Corporate Officer/Principal presso CellAegis Devices, Inc.
Profilo
Vera Belaoussoff is currently the Vice President-Corporate Development at CellAegis Devices, Inc. She previously worked as the Director-Preclinical & Scientific Policy at YM BioSciences, Inc. She has a graduate degree from York University and an undergraduate degree from the University of Manitoba, which she received in 1986.
Posizioni attive di Vera Belaoussoff
Società | Posizione | Inizio |
---|---|---|
CellAegis Devices, Inc.
CellAegis Devices, Inc. Electronic Equipment/InstrumentsElectronic Technology CellAegis Devices, Inc. develops device for the treatment of cardiac patients. . It offers autoRIC Device, an automated noninvasive device that provides point of care delivery of remote ischemic conditioning. The company was founded by John Berton, Andrew N. Redington and Christopher Caldarone and is headquartered in Toronto, Canada. | Corporate Officer/Principal | - |
Precedenti posizioni note di Vera Belaoussoff
Società | Posizione | Fine |
---|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formazione di Vera Belaoussoff
York University | Graduate Degree |
University of Manitoba | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
CellAegis Devices, Inc.
CellAegis Devices, Inc. Electronic Equipment/InstrumentsElectronic Technology CellAegis Devices, Inc. develops device for the treatment of cardiac patients. . It offers autoRIC Device, an automated noninvasive device that provides point of care delivery of remote ischemic conditioning. The company was founded by John Berton, Andrew N. Redington and Christopher Caldarone and is headquartered in Toronto, Canada. | Electronic Technology |
- Borsa valori
- Insiders
- Vera Belaoussoff